There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for KAPA is 7.12M and currently, short sellers hold a 1.20% ratio of that float. The average trading volume of KAPA on June 10, 2025 was 443.75K shares.
KAPA) stock’s latest price update
The stock price of Kairos Pharma Ltd (AMEX: KAPA) has surged by 19.79 when compared to previous closing price of 0.47, but the company has seen a -3.70% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-06-03 that LOS ANGELES–(BUSINESS WIRE)–Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces its presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting highlighting data on its investigational small molecule GITR ligand agonist KROS101. ASCO is being held May 30-June 3, 2025 at McCormick Place in Chicago, Ill. In the presentation titled, “Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and.
KAPA’s Market Performance
KAPA’s stock has fallen by -3.70% in the past week, with a monthly drop of -24.95% and a quarterly drop of -38.41%. The volatility ratio for the week is 12.31% while the volatility levels for the last 30 days are 9.54% for Kairos Pharma Ltd The simple moving average for the past 20 days is -1.52% for KAPA’s stock, with a -55.71% simple moving average for the past 200 days.
KAPA Trading at -26.44% from the 50-Day Moving Average
After a stumble in the market that brought KAPA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.83% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at KAPA starting from Murali Ramachandran, who purchase 200 shares at the price of $1.59 back on Nov 25 ’24. After this action, Murali Ramachandran now owns 133,057 shares of Kairos Pharma Ltd, valued at $318 using the latest closing price.
Samuelson Doug, the Chief Financial Officer of Kairos Pharma Ltd, purchase 2,500 shares at $1.50 during a trade that took place back on Nov 22 ’24, which means that Samuelson Doug is holding 60,796 shares at $3,750 based on the most recent closing price.
Stock Fundamentals for KAPA
The total capital return value is set at -0.47. Equity return is now at value -149.74, with -79.52 for asset returns.
Currently, EBITDA for the company is -2.34 million with net debt to EBITDA at 1.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.52.
Conclusion
In conclusion, Kairos Pharma Ltd (KAPA) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
